Rtw Investments Adds $8M in Ocugen, Inc. ($OCGN)
RTW Investments has initiated a new position in OCGN with 6.67 million shares.
Key Points
- RTW Investments has acquired 6.67 million shares of OCGN, valued at approximately $8.07 million, as of its latest SEC filing.
- OCGN shares are trading at $1.21, with prominent funds like Vanguard and BlackRock also holding significant positions.
- Analysts from Canaccord Genuity and HC Wainwright & Co. have maintained 'buy' ratings on OCGN, with price targets ranging from $7 to $12.
RTW Investments has taken a new position in OCGN, acquiring 6.67 million shares. This stake is valued at about $8.07 million, according to the latest Form 13F filing with the SEC. The filing reflects RTW's holdings as of the end of the reporting period and may not indicate its current position.
What Changed in RTW Investments' OCGN Position
RTW Investments' acquisition of 6.67 million shares marks a new entry into OCGN. The shares are valued at approximately $8.07 million, with a cost basis of $1.88 per share. This is a fresh position for RTW, as they previously held no shares in the company.
Other Institutional Activity in OCGN
Vanguard Capital Management LLC expanded its holdings significantly by adding 13,804,111 shares, bringing its total to about 13.8 million shares worth $24.99 million. Millennium Management LLC also increased its position by 8,330,775 shares, ending with 13.7 million shares valued at $24.85 million. State Street Corp's stake grew by 5,691,453 shares, now totaling 9.67 million shares worth $17.5 million. Marshall Wace, LLP added 5,521,394 shares, reaching 8.05 million shares valued at $14.57 million. BlackRock, Inc. increased its holdings by 2,748,435 shares, resulting in 7.3 million shares worth $13.22 million.
OCGN Stock Snapshot
Shares of OCGN are currently trading at $1.21. The company has seen significant interest from institutional investors, with notable changes in holdings by major funds. OCGN's stock performance and institutional backing suggest ongoing interest in its potential.
Insider Buying and Selling at Ocugen, Inc.
On April 1, 2026, Zhang Junge acquired 194,134 shares at an average price of $0.7948. Earlier in the year, on January 2, 2026, CEO Shankar Musunuri bought 3,123,201 shares, while Chief Accounting Officer Ramesh Ramachandran purchased 207,300 shares. These transactions were not part of any pre-scheduled trading plans.
Analysts Set New Price Targets
On May 27, 2026, Canaccord Genuity maintained a 'buy' rating on OCGN with a price target of $11. HC Wainwright & Co. reiterated their 'buy' rating on March 25, 2026, with a target of $10. Canaccord Genuity had also initiated coverage with a 'buy' rating and a $12 target on March 17, 2026. The consensus among analysts is a 'buy' recommendation, with an average price target reflecting bullish sentiment.
About OCGN
OCGN is a biotechnology company focused on discovering, developing, and commercializing transformative therapies to treat eye diseases and other serious conditions. The company operates in the healthcare sector and is based in the United States.
Bottom Line
RTW Investments' new position in OCGN underscores a growing interest in the stock among institutional investors. While the 13F filing offers a snapshot of the past quarter's holdings, investors should note that these filings are retrospective and may not reflect current positions. OCGN's stock continues to attract attention from both analysts and institutional players, highlighting its potential in the biotechnology sector.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.